ArticleBMC cancer2021

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.

Petros Christopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.